BRPI0618399A2 - região de ligação de antìgeno isolada que é especìfica para cd38, anticorpo isolado ou um fragmento funcional do mesmo que é especìfico para cd38, anticorpo isolado ou um fragmento funcional do mesmo, imunoglobulina isolada, cadeia pesada variável de uma região de ligação de antìgeno isolada, cadeia leve variável de uma região de ligação de antìgeno isolada, seqüência isolada de ácido nucléico, seqüência de ácido nucléico que codifica uma cadeia pesada variável de uma região de ligação de antìgeno isolada, seqüência de ácido nucléico, vetor, célula isolada, composição farmacêutica, uso da composição farmacêutica, método de indução de mortandade especìfica das células de tumor que expressam cd38, método de detecção da mortandade especìfica das células de tumor que expressam cd38, método de detecção da presença de cd38 em um tecido ou em célula de origem de miniporco, método de detecção de cd38 em um eritrócito que expressa cd38 e composição de diagnóstico - Google Patents
região de ligação de antìgeno isolada que é especìfica para cd38, anticorpo isolado ou um fragmento funcional do mesmo que é especìfico para cd38, anticorpo isolado ou um fragmento funcional do mesmo, imunoglobulina isolada, cadeia pesada variável de uma região de ligação de antìgeno isolada, cadeia leve variável de uma região de ligação de antìgeno isolada, seqüência isolada de ácido nucléico, seqüência de ácido nucléico que codifica uma cadeia pesada variável de uma região de ligação de antìgeno isolada, seqüência de ácido nucléico, vetor, célula isolada, composição farmacêutica, uso da composição farmacêutica, método de indução de mortandade especìfica das células de tumor que expressam cd38, método de detecção da mortandade especìfica das células de tumor que expressam cd38, método de detecção da presença de cd38 em um tecido ou em célula de origem de miniporco, método de detecção de cd38 em um eritrócito que expressa cd38 e composição de diagnóstico Download PDFInfo
- Publication number
- BRPI0618399A2 BRPI0618399A2 BRPI0618399-9A BRPI0618399A BRPI0618399A2 BR PI0618399 A2 BRPI0618399 A2 BR PI0618399A2 BR PI0618399 A BRPI0618399 A BR PI0618399A BR PI0618399 A2 BRPI0618399 A2 BR PI0618399A2
- Authority
- BR
- Brazil
- Prior art keywords
- isolated
- antigen binding
- binding region
- specific
- nucleic acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Abstract
REGIAO DE LIGAçãO DE ANTìGENO ISOLADA QUE é ESPECìFICA PARA CD38, ANTICORPO ISOLADO OU UM FRAGMENTO FUNCIONAL DO MESMO QUE é ESPECìFICO PARA CD38, ANTICORPO ISOLADO OU UM FRAGMENTO FUNCIONAL DO MESMO, IMUNOGLOBULINA ISOLADA, CADEIA PESADA VARIáVEL DE UMA REGIAO DE LIGAçAO DE ANTìGENO ISOLADA, CADEIA LEVE VARIáVEL DE UMA REGIAO DE LIGAçAO DE ANTìGENO ISOLADA, SEQUêNCIA ISOLADA DE áCIDO NUCLéICO, SEQUêNCIA DE áCIDO NUCLéICO QUE CODIFICA UMA CADEIA PESADA VARIáVEL DE UMA REGIAO DE LIGAçAO DE ANTìGENO ISOLADA, SEQUêNCIA DE áCIDO NUCLEICO, VETOR, CéLULA ISOLADA, COMPOSIçAO FARMACêUTICA, USO DA COMPOSIçAO FARMACêUTICA, MéTODO DE INDUçAO DE MORTANDADE ESPECìFICA DAS CéLULAS DE TUMOR QUE EXPRESSAM CD38, MéTODO DE DETECçAO DA MORTANDADE ESPECìFICA DAS CéLULAS DE TUMOR QUE EXPRESSAM CD38, MéTODO DE DETECçAO DA PRESENçA DE CD38 EM UM TECIDO OU EM UMA CéLULA DE ORIGEM DE MINIPORCO, MéTODO DE DETECçAO DE CD38 EM UM ERITRóCITO QUE EXPRESSA CD38 E COMPOSIçAO DE DIAGNóSTICO A presente invenção apresenta novos anticorpos e métodos para a utilização de regiões de ligação de antígenorecombinante e anticorpos e fragmentos funcionais que contêm tais regiões de ligação de antígeno que são específicas para CD38, que desempenha um papel integral em vários distúrbios ou condições. Esses métodos se beneficiam dos anticorpos recentemente descobertos e das propriedades surpreendentes de tais anticorpos, tais como a capacidade de se ligar ao CD38 de origem de miniporco e a capacidade de induzir, por reticulação, uma mortandade específica de células que expressam CD38. Esses anticorpos, bem como os novos métodos para a utilização desses anticorpos, podem ser utilizados para o tratamento, por exemplo, de malignidades hematológicas tais como o mieloma múltiplo.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72529705P | 2005-10-12 | 2005-10-12 | |
| US60/725,297 | 2005-10-12 | ||
| PCT/EP2006/009889 WO2007042309A2 (en) | 2005-10-12 | 2006-10-12 | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BRPI0618399A2 true BRPI0618399A2 (pt) | 2011-08-30 |
| BRPI0618399B1 BRPI0618399B1 (pt) | 2023-10-03 |
Family
ID=37467440
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0618399-9A BRPI0618399B1 (pt) | 2005-10-12 | 2006-10-12 | Anticorpo específico anti-cd38 humano, composição de ácido nucleico, vetor de expressão, composição farmacêutica, uso do anticorpo e uso de uma composição farmacêutica |
Country Status (29)
| Country | Link |
|---|---|
| US (6) | US8088896B2 (pt) |
| EP (3) | EP3284756B1 (pt) |
| JP (2) | JP5362359B2 (pt) |
| KR (4) | KR101574920B1 (pt) |
| CN (4) | CN101287764B (pt) |
| AR (2) | AR055191A1 (pt) |
| AU (1) | AU2006301446B2 (pt) |
| BR (1) | BRPI0618399B1 (pt) |
| CA (1) | CA2625681C (pt) |
| CY (1) | CY1119722T1 (pt) |
| DK (1) | DK2860192T3 (pt) |
| ES (1) | ES2653664T3 (pt) |
| HK (2) | HK1122822A1 (pt) |
| HR (1) | HRP20171978T1 (pt) |
| HU (1) | HUE035250T2 (pt) |
| IL (1) | IL190665B (pt) |
| LT (1) | LT2860192T (pt) |
| ME (1) | ME02886B (pt) |
| NO (1) | NO344961B1 (pt) |
| NZ (1) | NZ566915A (pt) |
| PL (1) | PL2860192T3 (pt) |
| PT (1) | PT2860192T (pt) |
| RS (1) | RS56677B1 (pt) |
| RU (1) | RU2425841C2 (pt) |
| SG (1) | SG10201400973XA (pt) |
| SI (1) | SI2860192T1 (pt) |
| TW (1) | TWI428444B (pt) |
| WO (1) | WO2007042309A2 (pt) |
| ZA (1) | ZA200803208B (pt) |
Families Citing this family (108)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9200061B2 (en) * | 2004-02-06 | 2015-12-01 | Morpho Sys AG | Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i |
| TWI428444B (zh) | 2005-10-12 | 2014-03-01 | Morphosys Ag | 由全長人類ＨｕＣＡＬ ＧＯＬＤ-衍生之對人類ＣＤ３８有特異性之治療抗體之產生及鑑定 |
| PE20090368A1 (es) | 2007-06-19 | 2009-04-28 | Boehringer Ingelheim Int | Anticuerpos anti-igf |
| PE20090499A1 (es) | 2007-08-09 | 2009-05-18 | Boehringer Ingelheim Int | Anticuerpos anti-cd37 |
| UY32317A (es) * | 2008-12-12 | 2010-07-30 | Boehringer Ingelheim Int | Anticuerpos anti-igf |
| US20100291106A1 (en) * | 2009-05-06 | 2010-11-18 | Novartis Ag | Compositions and methods for antibodies targeting complement protein c3b |
| RU2595839C2 (ru) | 2010-09-27 | 2016-08-27 | МорфоСис АГ | Антитело к cd38 и леналидомид или бортезомиб для лечения множественной миеломы и nhl |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| WO2013010955A1 (en) * | 2011-07-15 | 2013-01-24 | Morphosys Ag | Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt) |
| US20130122005A1 (en) | 2011-10-27 | 2013-05-16 | Paul Adam | Anticancer combination therapy |
| KR102037541B1 (ko) | 2011-10-28 | 2019-10-29 | 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 | 폴리펩티드 구축물 및 이의 용도 |
| CA2859493A1 (en) | 2011-12-21 | 2013-06-27 | Novartis Ag | Compositions and methods for antibodies targeting factor p |
| EP2843051B1 (en) | 2012-04-23 | 2018-06-06 | GeneFrontier Corporation | Anti-human cd69 antibody, and use thereof for medical purposes |
| CA2885792C (en) * | 2012-09-25 | 2021-09-28 | Jan Endell | Pharmaceutical combination of an anti-cd38 antibody and melphalan for treating multiple myeloma |
| DK2914302T3 (en) | 2012-11-05 | 2017-04-10 | Morphosys Ag | RADIOACTIVALLY MARKED ANTIBODY AND USES OF IT |
| CN108424453B (zh) | 2012-11-09 | 2021-08-06 | 基因先端领域株式会社 | 用于治疗癌症的抗adam28抗体 |
| US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
| CN110981964B (zh) | 2013-01-14 | 2023-09-15 | Xencor股份有限公司 | 新型异二聚体蛋白 |
| US20140255413A1 (en) | 2013-03-07 | 2014-09-11 | Boehringer Ingelheim International Gmbh | Combination therapy for neoplasia treatment |
| MY175418A (en) * | 2013-03-13 | 2020-06-24 | Sanofi Sa | Compositions comprising anti-cd38 antibodies and carfilzomib |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| EA033115B1 (ru) | 2013-04-29 | 2019-08-30 | Тева Фармасьютикалз Острэйлиа Пти Лтд. | АНТИТЕЛА ПРОТИВ CD38 И СЛИТЫЕ БЕЛКИ С ОСЛАБЛЕННЫМ ИНТЕРФЕРОНОМ АЛЬФА-2b |
| US11117975B2 (en) | 2013-04-29 | 2021-09-14 | Teva Pharmaceuticals Australia Pty Ltd | Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B |
| JP5892117B2 (ja) * | 2013-07-17 | 2016-03-23 | 横河電機株式会社 | フィールド機器及び通信システム |
| CN103513040B (zh) * | 2013-10-16 | 2015-03-11 | 常晓天 | 蛋白cd38在制备类风湿性关节炎诊断标记物中的应用 |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| KR102497443B1 (ko) | 2014-03-28 | 2023-02-08 | 젠코어 인코포레이티드 | Cd38 및 cd3에 결합하는 이중특이적 항체 |
| UA119352C2 (uk) | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину |
| EP3175289A4 (en) | 2014-08-03 | 2018-04-18 | Pogotec, Inc. | Wearable camera systems and apparatus and method for attaching camera systems or other electronic devices to wearable articles |
| WO2016040294A2 (en) | 2014-09-09 | 2016-03-17 | Janssen Biotech, Inc. | Combination therapies with anti-cd38 antibodies |
| IL251822B2 (en) | 2014-10-29 | 2023-03-01 | Teva Pharmaceuticals Australia Pty Ltd | Variants of interferon alpha-2-b |
| MA40894A (fr) * | 2014-11-04 | 2017-09-12 | Glenmark Pharmaceuticals Sa | Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production |
| US11773166B2 (en) | 2014-11-04 | 2023-10-03 | Ichnos Sciences SA | CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production |
| CA2967426A1 (en) | 2014-11-26 | 2016-06-02 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and tumor antigens |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| PE20171103A1 (es) | 2014-11-26 | 2017-08-07 | Xencor Inc | Anticuerpos heterodimericos que se unen a cd3 y cd38 |
| SG11201704390PA (en) * | 2014-12-04 | 2017-06-29 | Janssen Biotech Inc | Anti-cd38 antibodies for treatment of acute myeloid leukemia |
| US10329358B2 (en) | 2015-03-06 | 2019-06-25 | Genefrontier Corporation | Anti-human membrane-type ADAM28 antibody |
| WO2016164656A1 (en) * | 2015-04-08 | 2016-10-13 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind cd38 |
| CA2984464C (en) | 2015-05-13 | 2023-10-10 | Morphosys Ag | Treatment for multiple myeloma (mm) |
| BR112017024877A2 (pt) | 2015-05-20 | 2019-09-17 | Janssen Biotech, Inc. | anticorpo anti-cd38 e seu uso no tratamento de amiloidose de cadeia leve e outras malignidades hematológicas positivas para cd38 |
| CA2990406A1 (en) * | 2015-06-22 | 2016-12-29 | Janssen Biotech, Inc. | Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors |
| US20160376373A1 (en) | 2015-06-24 | 2016-12-29 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
| EA202190808A2 (ru) | 2015-11-03 | 2021-12-31 | Янссен Байотек, Инк. | Составы антител к cd38 для подкожного введения и их применение |
| CN108699136B (zh) | 2015-12-07 | 2022-03-18 | Xencor股份有限公司 | 结合cd3和psma的异二聚抗体 |
| AU2017226960B2 (en) | 2016-03-04 | 2024-03-21 | Morphosys Ag | Clinical assessment of M-protein response in multiple myeloma |
| KR102405278B1 (ko) | 2016-04-22 | 2022-06-07 | 악셀레론 파마 인코포레이티드 | Alk7 결합 단백질 및 이들의 용도 |
| RU2022104399A (ru) | 2016-06-14 | 2022-05-05 | Ксенкор, Инк. | Биспецифические антитела-ингибиторы контрольных точек |
| WO2018002181A1 (en) | 2016-06-28 | 2018-01-04 | Umc Utrecht Holding B.V. | TREATMENT OF IgE-MEDIATED DISEASES WITH ANTIBODIES THAT SPECIFICALLY BIND CD38 |
| WO2018015498A1 (en) | 2016-07-20 | 2018-01-25 | Hybrigenics Sa | Combinations of inecalcitol with an anti-cd38 agent and their uses for treating cancer |
| JOP20190009A1 (ar) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
| MX2019004621A (es) | 2016-11-02 | 2019-11-28 | Engmab Sarl | Anticuerpo biespecifico contra bcma y cd3 y un farmaco inmunologico para uso combinado en el tratamiento del mieloma multiple. |
| EP3360898A1 (en) | 2017-02-14 | 2018-08-15 | Boehringer Ingelheim International GmbH | Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer |
| CN111051344B (zh) | 2017-06-08 | 2023-10-27 | 黑带医疗有限公司 | Cd38调节抗体 |
| US11542338B2 (en) | 2017-08-16 | 2023-01-03 | Black Belt Therapeutics Limited | CD38 modulating antibody |
| CA3072296A1 (en) * | 2017-08-16 | 2019-02-21 | Black Belt Therapeutics Limited | Cd38 antibody |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| US20200207867A1 (en) | 2017-09-13 | 2020-07-02 | Teneobio, Inc. | Heavy chain antibodies binding to ectoenzymes |
| BR112020005028A2 (pt) | 2017-09-14 | 2020-09-15 | Glaxosmithkline Intellectual Property Development Limited | tratamento em combinação para câncer |
| MA50514A (fr) | 2017-10-31 | 2020-09-09 | Janssen Biotech Inc | Méthodes de traitement du myélome multiple à haut risque |
| JP2021501587A (ja) | 2017-11-03 | 2021-01-21 | ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | Ｃｄ３８指向性キメラ抗原受容体構築物 |
| CN116731173A (zh) * | 2017-12-14 | 2023-09-12 | Abl生物公司 | 抗a-syn/igf1r的双特异性抗体及其用途 |
| CN110144008B (zh) | 2018-02-12 | 2021-03-19 | 杭州尚健生物技术有限公司 | Cd38蛋白抗体及其应用 |
| KR20200133376A (ko) | 2018-03-21 | 2020-11-27 | 알렉소 온콜로지 인크. | 신호-조절 단백질 알파에 대한 항체 및 사용 방법 |
| CA3100118A1 (en) | 2018-05-16 | 2019-11-21 | Janssen Biotech, Inc. | Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy |
| EP3569618A1 (en) | 2018-05-19 | 2019-11-20 | Boehringer Ingelheim International GmbH | Antagonizing cd73 antibody |
| TW202016151A (zh) | 2018-06-09 | 2020-05-01 | 德商百靈佳殷格翰國際股份有限公司 | 針對癌症治療之多特異性結合蛋白 |
| WO2019245616A1 (en) * | 2018-06-20 | 2019-12-26 | Sorrento Therapeutics, Inc. | Variant antibody that binds cd38 |
| EP3820890A1 (en) | 2018-07-13 | 2021-05-19 | Genmab A/S | Trogocytosis-mediated therapy using cd38 antibodies |
| SG11202012993SA (en) | 2018-07-13 | 2021-02-25 | Genmab As | Variants of cd38 antibody and uses thereof |
| AU2019338999A1 (en) | 2018-09-11 | 2021-03-18 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-CD38 antibody, antigen-binding fragment thereof, and pharmaceutical use |
| CN109293773B (zh) * | 2018-09-25 | 2020-09-04 | 上海邦耀生物科技有限公司 | 靶向cd38蛋白的抗体、嵌合抗原受体和药物 |
| BR112021007227A2 (pt) | 2018-10-17 | 2021-08-10 | Janssen Biotech, Inc. | método para fornecer administração subcutânea de anticorpos anti-cd38 |
| KR20210086651A (ko) | 2018-10-26 | 2021-07-08 | 테네오바이오, 인코포레이티드 | Cd38에 결합하는 중쇄 항체 |
| BR112021008879A2 (pt) | 2018-11-13 | 2021-10-26 | Janssen Biotech, Inc. | Controle de oligometais durante a produção de anticorpos anti-cd38 |
| SG11202104012QA (en) | 2018-12-14 | 2021-05-28 | Morphosys Ag | Antibody formulations |
| BR112021014574A2 (pt) * | 2019-01-23 | 2021-10-05 | Encefa | Competidores cd31 e usos dos mesmos |
| WO2020187718A1 (en) | 2019-03-15 | 2020-09-24 | Morphosys Ag | Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease |
| AU2020299600A1 (en) * | 2019-07-03 | 2022-01-06 | Crystal Bioscience Inc. | Anti-CD38 antibody and methods of use thereof |
| JP2022548925A (ja) * | 2019-09-18 | 2022-11-22 | モメンタ ファーマシューティカルズ インコーポレイテッド | ＣＤ３８を標的とした改変されたＦｃ抗原結合ドメイン構築物に関する組成物及び方法 |
| TW202128756A (zh) | 2019-10-02 | 2021-08-01 | 德商百靈佳殷格翰國際股份有限公司 | 用於癌症治療之多重專一性結合蛋白 |
| GB201916150D0 (en) | 2019-11-06 | 2019-12-18 | Univ Of Ireland Galway | Treatment of multiple myeloma |
| WO2021112196A1 (ja) * | 2019-12-05 | 2021-06-10 | 学校法人東京薬科大学 | 筋組織の減少を抑制するための組成物 |
| CN115023441A (zh) | 2019-12-18 | 2022-09-06 | 特诺福尔股份有限公司 | 与cd38结合的重链抗体 |
| JP2023510397A (ja) | 2020-01-16 | 2023-03-13 | ジェンマブ エー／エス | Ｃｄ３８抗体の製剤およびその使用 |
| US11919956B2 (en) | 2020-05-14 | 2024-03-05 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3 |
| AU2021276332A1 (en) | 2020-05-19 | 2022-11-17 | Boehringer Ingelheim International Gmbh | Binding molecules for the treatment of cancer |
| CN111808193B (zh) * | 2020-06-30 | 2022-04-05 | 源道隆（苏州）医学科技有限公司 | 可结合人cd38的纳米抗体及其应用 |
| CN113861292A (zh) * | 2020-06-30 | 2021-12-31 | 百奥泰生物制药股份有限公司 | 抗cd40抗体或抗原结合片段及其应用 |
| KR102607909B1 (ko) | 2020-08-19 | 2023-12-01 | 젠코어 인코포레이티드 | 항-cd28 조성물 |
| EP4232476A2 (en) | 2020-10-21 | 2023-08-30 | Boehringer Ingelheim International GmbH | Agonistic trkb binding molecules for the treatment of eye diseases |
| AU2022208200A1 (en) | 2021-01-14 | 2023-07-20 | Morphosys Ag | Anti-cd38 antibodies and their uses |
| US20220275090A1 (en) | 2021-02-22 | 2022-09-01 | Janssen Biotech, Inc. | Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors |
| TW202302642A (zh) | 2021-03-01 | 2023-01-16 | 德商莫菲西斯公司 | 用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體 |
| CA3212665A1 (en) | 2021-03-09 | 2022-09-15 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cldn6 |
| KR20230154311A (ko) | 2021-03-10 | 2023-11-07 | 젠코어 인코포레이티드 | Cd3 및 gpc3에 결합하는 이종이량체 항체 |
| EP4355778A1 (en) | 2021-06-17 | 2024-04-24 | Boehringer Ingelheim International GmbH | Novel tri-specific binding molecules |
| WO2022271987A1 (en) | 2021-06-23 | 2022-12-29 | TeneoFour, Inc. | Anti-cd38 antibodies and epitopes of same |
| TW202321303A (zh) | 2021-07-19 | 2023-06-01 | 德商莫菲西斯公司 | 抗pla2r自體抗體媒介膜性腎病變之治療 |
| IL310372A (en) | 2021-07-28 | 2024-03-01 | Genentech Inc | IL15/IL15R alpha heterodimeric FC-fused proteins for the treatment of blood cancer |
| WO2023079494A1 (en) | 2021-11-03 | 2023-05-11 | Janssen Biotech, Inc. | Corticosteriod reduction in treatment with anti-cd38 antibodies |
| WO2023143547A1 (zh) * | 2022-01-30 | 2023-08-03 | 百奥泰生物制药股份有限公司 | 抗cd28抗体及其应用 |
| WO2023144303A1 (en) | 2022-01-31 | 2023-08-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Cd38 as a biomarker and biotarget in t-cell lymphomas |
| WO2023240135A2 (en) | 2022-06-07 | 2023-12-14 | Actinium Pharmaceuticals, Inc. | Bifunctional chelators and conjugates |
| US20240052065A1 (en) | 2022-07-15 | 2024-02-15 | Boehringer Ingelheim International Gmbh | Binding molecules for the treatment of cancer |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| EP0250486A4 (en) * | 1986-01-03 | 1988-05-25 | Univ Melbourne | MELPHALAN DERIVATIVES. |
| SU1595902A1 (ru) * | 1988-06-30 | 1990-09-30 | Всесоюзный онкологический научный центр АМН СССР | Штамм гибридных культивируемых клеток животных MUS мUSсULUS L, используемый дл получени моноклональных антител к антигену СД38 кортикальных тимоцитов |
| US5156951A (en) * | 1989-07-13 | 1992-10-20 | Becton Dickinson And Company | Detecting immunological changes in HIV infected patient samples |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| GB9022543D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
| AU6123894A (en) | 1993-01-29 | 1994-08-15 | Board Of Trustees Of The Leland Stanford Junior University | Modulation of physiological responses of lymphocytes by cd38 or antibodies thereto |
| US6555324B1 (en) | 1993-11-04 | 2003-04-29 | Becton Dickinson & Company | Method to distinguish hematopoietic progenitor cells |
| GB9424449D0 (en) * | 1994-12-02 | 1995-01-18 | Wellcome Found | Antibodies |
| US20020164788A1 (en) | 1994-12-02 | 2002-11-07 | The Wellcome Foundation Limited | Humanized antibodies to CD38 |
| WO1996035782A1 (en) | 1995-05-11 | 1996-11-14 | Applied Research Systems | Il-6 activity inhibitor |
| WO1997008320A1 (en) | 1995-08-18 | 1997-03-06 | Morphosys Gesellschaft Für Proteinoptimierung Mbh | Protein/(poly)peptide libraries |
| US5594116A (en) | 1995-11-08 | 1997-01-14 | Promega Corporation | Tryptase polyclonal antibody and purification method for use in human tryptase immunoassay |
| JP4233608B2 (ja) * | 1996-10-15 | 2009-03-04 | 塩野義製薬株式会社 | 自己抗体測定方法 |
| AU770718B2 (en) | 1998-06-05 | 2004-02-26 | Mayo Foundation For Medical Education And Research | Use of genetically engineered antibodies to CD38 to treat multiple myeloma |
| US7223397B1 (en) | 1999-01-07 | 2007-05-29 | Research Development Foundation | Potentiation of anti-CD38-Immunotoxin cytotoxicity |
| GB9903664D0 (en) | 1999-02-17 | 1999-04-14 | Isis Innovation | Adjuvant and cell maturation agent |
| JP2000316578A (ja) | 1999-05-12 | 2000-11-21 | Bml Inc | 糖尿病発症危険因子の検出方法 |
| EP1990409A3 (en) | 1999-07-20 | 2011-05-18 | MorphoSys AG | Bacteriophage |
| US7442776B2 (en) * | 1999-10-08 | 2008-10-28 | Young David S F | Cancerous disease modifying antibodies |
| US20020028488A1 (en) | 2000-06-19 | 2002-03-07 | Sujay Singh | Transgenic avian species for making human and chimeric antibodies |
| EP1174440A1 (en) | 2000-07-19 | 2002-01-23 | U-BISys B.V. | A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment |
| JP4139214B2 (ja) | 2000-10-17 | 2008-08-27 | トリュデュ インスティチュート，インク． | Ｃｄ３８により調節される走化性 |
| US20070042436A1 (en) | 2000-10-17 | 2007-02-22 | Lund Frances E | CD38 modulated chemotaxis |
| US6892140B1 (en) | 2000-11-27 | 2005-05-10 | Enteron, Inc. | Immunogenic cancer peptides and uses thereof |
| US7361343B2 (en) * | 2003-01-21 | 2008-04-22 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD63 |
| DK1409646T3 (da) | 2000-12-19 | 2012-08-06 | Altor Bioscience Corp | Transgene dyr omfattende et humaniseret immunsystem |
| US20040081981A1 (en) | 2001-01-31 | 2004-04-29 | Toru Egashira | Method of detecting risk factor for onset of diabetes |
| DE60237969D1 (de) | 2001-04-24 | 2010-11-25 | Bayer Corp | Menschliche antikörper gegen timp-1 |
| WO2004003019A2 (en) * | 2002-06-28 | 2004-01-08 | Domantis Limited | Immunoglobin single variant antigen-binding domains and dual-specific constructs |
| US7084257B2 (en) | 2001-10-05 | 2006-08-01 | Amgen Inc. | Fully human antibody Fab fragments with human interferon-gamma neutralizing activity |
| JP3665324B2 (ja) | 2001-10-15 | 2005-06-29 | 麒麟麦酒株式会社 | 抗ｈｌａ−ｄｒ抗体 |
| AR038568A1 (es) | 2002-02-20 | 2005-01-19 | Hoffmann La Roche | Anticuerpos anti-a beta y su uso |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| WO2003091275A2 (en) | 2002-04-23 | 2003-11-06 | Andrea Savarino | Compositions containing anti-hiv peptides and methods of use |
| ITMI20021527A1 (it) | 2002-07-11 | 2004-01-12 | Consiglio Nazionale Ricerche | Anticorpi anti componente c5 del complemento e loro uso |
| US7393531B2 (en) * | 2003-01-21 | 2008-07-01 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of MCSP |
| WO2005042019A1 (en) | 2003-10-22 | 2005-05-12 | University Of Rochester | Anti-thymocyte antiserum and use thereof to trigger b cell apoptosis |
| US9200061B2 (en) | 2004-02-06 | 2015-12-01 | Morpho Sys AG | Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i |
| AU2005235811B2 (en) | 2004-02-06 | 2011-11-03 | Morphosys Ag | Anti-CD38 human antibodies and uses therefor |
| EP1720907B1 (en) | 2004-02-06 | 2015-04-08 | MorphoSys AG | Anti-cd38 human antibodies and uses therefor |
| ATE446315T1 (de) | 2004-02-13 | 2009-11-15 | Boehringer Ingelheim Pharma | Cd38-spleiss-varianten und deren anwendungen |
| SG10201912554TA (en) | 2005-03-23 | 2020-02-27 | Genmab As | Antibodies against cd38 for treatment of multiple myeloma |
| WO2006110585A2 (en) | 2005-04-07 | 2006-10-19 | Novartis Vaccines And Diagnostics Inc. | Cancer-related genes (prlr) |
| EP1888647A2 (en) * | 2005-05-24 | 2008-02-20 | MorphoSys AG | Generation and profiling of fully human hucal gold®-derived therapeutic antibodies specific for human cd38 |
| TWI428444B (zh) | 2005-10-12 | 2014-03-01 | Morphosys Ag | 由全長人類ＨｕＣＡＬ ＧＯＬＤ-衍生之對人類ＣＤ３８有特異性之治療抗體之產生及鑑定 |
| GB0603683D0 (en) * | 2006-02-23 | 2006-04-05 | Novartis Ag | Organic compounds |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| HUE027683T2 (en) | 2007-10-01 | 2016-10-28 | Codexis Inc | Ketoreductase polypeptides for the production of azetidinone |
| WO2011045704A1 (en) | 2009-10-12 | 2011-04-21 | Pfizer Inc. | Cancer treatment |
| RU2595839C2 (ru) * | 2010-09-27 | 2016-08-27 | МорфоСис АГ | Антитело к cd38 и леналидомид или бортезомиб для лечения множественной миеломы и nhl |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| CA2885792C (en) * | 2012-09-25 | 2021-09-28 | Jan Endell | Pharmaceutical combination of an anti-cd38 antibody and melphalan for treating multiple myeloma |
| DK2914302T3 (en) * | 2012-11-05 | 2017-04-10 | Morphosys Ag | RADIOACTIVALLY MARKED ANTIBODY AND USES OF IT |
| US11920830B1 (en) | 2022-11-11 | 2024-03-05 | Russell Dwayne Mcnally | Tool and method for cleaning and draining a water heater |
-
2006
- 2006-10-12 TW TW095137628A patent/TWI428444B/zh active
- 2006-10-12 RU RU2008111882/10A patent/RU2425841C2/ru active
- 2006-10-12 PT PT141969725T patent/PT2860192T/pt unknown
- 2006-10-12 KR KR1020147020460A patent/KR101574920B1/ko active IP Right Grant
- 2006-10-12 KR KR1020157034098A patent/KR20150139636A/ko not_active Application Discontinuation
- 2006-10-12 CN CN2006800379242A patent/CN101287764B/zh active Active
- 2006-10-12 HU HUE14196972A patent/HUE035250T2/hu unknown
- 2006-10-12 AU AU2006301446A patent/AU2006301446B2/en active Active
- 2006-10-12 PL PL14196972T patent/PL2860192T3/pl unknown
- 2006-10-12 JP JP2008534940A patent/JP5362359B2/ja active Active
- 2006-10-12 US US12/089,806 patent/US8088896B2/en active Active
- 2006-10-12 DK DK14196972.5T patent/DK2860192T3/en active
- 2006-10-12 CA CA2625681A patent/CA2625681C/en active Active
- 2006-10-12 BR BRPI0618399-9A patent/BRPI0618399B1/pt active IP Right Grant
- 2006-10-12 RS RS20171300A patent/RS56677B1/sr unknown
- 2006-10-12 KR KR1020137033870A patent/KR101472250B1/ko active IP Right Grant
- 2006-10-12 KR KR1020087011301A patent/KR101512853B1/ko active IP Right Grant
- 2006-10-12 EP EP17193089.4A patent/EP3284756B1/en active Active
- 2006-10-12 ES ES14196972.5T patent/ES2653664T3/es active Active
- 2006-10-12 NZ NZ566915A patent/NZ566915A/en unknown
- 2006-10-12 LT LTEP14196972.5T patent/LT2860192T/lt unknown
- 2006-10-12 AR ARP060104476A patent/AR055191A1/es active IP Right Grant
- 2006-10-12 CN CN201310495574.6A patent/CN103554260A/zh active Pending
- 2006-10-12 WO PCT/EP2006/009889 patent/WO2007042309A2/en active Application Filing
- 2006-10-12 ME MEP-2017-289A patent/ME02886B/me unknown
- 2006-10-12 EP EP06806243A patent/EP1945671A2/en not_active Withdrawn
- 2006-10-12 SG SG10201400973XA patent/SG10201400973XA/en unknown
- 2006-10-12 EP EP14196972.5A patent/EP2860192B1/en active Active
- 2006-10-12 SI SI200632232T patent/SI2860192T1/en unknown
- 2006-10-12 CN CN201310494874.2A patent/CN103554259B/zh active Active
- 2006-10-12 CN CN201510918061.0A patent/CN106434683B/zh active Active
-
2008
- 2008-04-07 IL IL190665A patent/IL190665B/en active IP Right Grant
- 2008-04-11 ZA ZA200803208A patent/ZA200803208B/xx unknown
- 2008-04-25 NO NO20081972A patent/NO344961B1/no unknown
- 2008-12-30 HK HK08114074.2A patent/HK1122822A1/xx unknown
-
2011
- 2011-11-08 US US13/291,473 patent/US8486394B2/en active Active
-
2012
- 2012-11-08 JP JP2012246686A patent/JP5752667B2/ja active Active
-
2013
- 2013-06-14 US US13/918,199 patent/US9193799B2/en active Active
-
2014
- 2014-07-31 HK HK14107873.1A patent/HK1194398A1/zh unknown
-
2015
- 2015-10-08 US US14/877,958 patent/US10184005B2/en active Active
-
2016
- 2016-07-26 AR ARP160102271A patent/AR105490A2/es not_active Application Discontinuation
-
2017
- 2017-12-19 CY CY20171101331T patent/CY1119722T1/el unknown
- 2017-12-20 HR HRP20171978TT patent/HRP20171978T1/hr unknown
-
2018
- 2018-09-07 US US16/125,307 patent/US11059902B2/en active Active
-
2021
- 2021-06-09 US US17/343,163 patent/US11939395B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0618399A2 (pt) | região de ligação de antìgeno isolada que é especìfica para cd38, anticorpo isolado ou um fragmento funcional do mesmo que é especìfico para cd38, anticorpo isolado ou um fragmento funcional do mesmo, imunoglobulina isolada, cadeia pesada variável de uma região de ligação de antìgeno isolada, cadeia leve variável de uma região de ligação de antìgeno isolada, seqüência isolada de ácido nucléico, seqüência de ácido nucléico que codifica uma cadeia pesada variável de uma região de ligação de antìgeno isolada, seqüência de ácido nucléico, vetor, célula isolada, composição farmacêutica, uso da composição farmacêutica, método de indução de mortandade especìfica das células de tumor que expressam cd38, método de detecção da mortandade especìfica das células de tumor que expressam cd38, método de detecção da presença de cd38 em um tecido ou em célula de origem de miniporco, método de detecção de cd38 em um eritrócito que expressa cd38 e composição de diagnóstico | |
| BR112022014667A2 (pt) | Anticorpos de domínio único de cd28 e construtos multivalentes e multiespecíficos dos mesmos | |
| CY1123708T1 (el) | Αντισωματα που συνδεονται προς τον ανθρωπινο προσδετη 1 (pd-l1) προγραμματισμενου θανατου | |
| EA200970477A1 (ru) | Человеческие моноклональные антитела к btla и способы применения | |
| BRPI0819909B8 (pt) | anticorpo sintético humano ou humanizado isolado ou um fragmento funcional do mesmo, fragmento funcional e composição farmacêutica | |
| BR112018007046A2 (pt) | anticorpo isolado ou fragmento de ligação a antígeno, composição farmacêutica, molécula de polinucleotídeo isolado, vetor, célula, e, métodos para inibir o crescimento de um tumor ou de uma célula tumoral e para tratar uma doença ou distúrbio. | |
| BR112018075737A2 (pt) | anticorpo, composição, célula isolada, e, métodos para tratar câncer ou infecção em um paciente e para detectar expressão de pd-l1 em uma amostra. | |
| EA200870021A1 (ru) | Человеческие моноклональные антитела к фукозил-gm1 и способы применения анти-фукозил-gm1 антител | |
| BR112012007365A2 (pt) | proteínas de ligação à il-1 | |
| CY1121538T1 (el) | Μονοκλωνικα αντισωματα εναντι του αναστολεα του μονοπατιου ιστικου παραγοντα (tfpi) | |
| BR112013004579A2 (pt) | proteína de ligação à mmp9, ácido nucleico, vetor, célula, composição farmacêutica e seu uso bem como método de detecção da expressão mmp9 | |
| BR112012023010A2 (pt) | "anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37" | |
| CY1116458T1 (el) | Ανθρωπινα αντισωματα anti-cd38 και οι χρησεις εξ' αυτων | |
| BR112016003369A2 (pt) | diacorpos monovalentes biespecíficos, diacorpos fc monovalentes biespecíficos, composição farmacêutica, uso da composição farmacêutica, célula que expressa uma cadeia de polipeptídeo de quaisquer dos diacorpos monovalentes biespecíficos, polinucleotídeo que codifica o polipeptídeo, e célula que expressa um anticorpo ou uma porção de polipeptídeo ou fragmento da mesma | |
| BR112018011100A2 (pt) | anticorpo, composição, construto de ácido nucleico, vetor de expressão, célula hospedeira, método para tratamento de um indivíduo que tem um câncer, kit de partes, e, uso de um anticorpo ou de uma composição. | |
| MX2010007406A (es) | Anticuerpos anti-factor inhibidor de migracion de macrofago (mif). | |
| BRPI0606790A2 (pt) | anticorpo humano isolado ou porção de ligação de antìgeno do mesmo, polipeptìdeo isolado, composição, ácido nucleico isolado, vetor de expressão célula hospedeira, vacina contra a raiva, kit, uso de um anticorpo monoclonal humano isolado ou porção de ligação de antìgeno do mesmo, ou de uma quantidade eficaz de uma composição, método para identificar um anticorpo ou um fragmento do mesmo, anticorpo ou fragmento do mesmo, anticorpo ou fragmento do mesmo,e, glicoproteìna. | |
| BR112013004266A2 (pt) | anticorpos anti-ox40 e métodos de uso dos mesmos. | |
| BR112015029953A2 (pt) | anticorpos anti-tweakr e seus usos | |
| NO20082559L (no) | Humane monoklonale antistoffer mot protein tyrosin kinase 7 (PTK7) og fremgangsmater for anvendelse av anti-PTK7 antistoffer | |
| CY1114719T1 (el) | Ανταγωνιστικα ανθρωπινου light-ειδικα ανθρωπινα μονοκλωνικα αντισωματα | |
| MX2018007630A (es) | Anticuerpos contra la metaloproteinasa de matriz 9. | |
| DE602005027399D1 (de) | Für humane matriptase spezifische bindungsproteine | |
| EA200901436A1 (ru) | Антигенсвязывающие белки, связывающие par-2 | |
| EA201101516A1 (ru) | Антитела, специфические для кадгерина-17 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B25G | Requested change of headquarter approved |
Owner name: MORPHOSYS AG (DE) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/10/2006, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |